IOVA - Iovance Biotherapeutics, Inc.
| Previous Close | 9.83 |
| Open | 9.70 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 800 |
| Day's Range | 9.61 - 10.02 |
| 52 Week Range | 6.60 - 19.90 |
| Volume | 1,653,133 |
| Avg. Volume | 1,423,723 |
| Market Cap | 1.184B |
| Beta (3Y Monthly) | 3.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.35 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.43 |
- GlobeNewswire•6 days ago
Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe
Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and MaSTherCell S.A., a subsidiary of Orgenesis Inc. (ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO), today announced that the two companies have entered into a new three-year Manufacturing Services Agreement. MaSTherCell will manufacture TIL for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites.
- GlobeNewswire•7 days ago
Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering
Iovance Biotherapeutics, Inc. (IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of an underwritten public offering of 25,300,000 shares of its common stock at a public offering price of $9.97 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are approximately $252.2 million. The shares of common stock issued and sold in the offering include 3,300,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price, less the underwriting discounts and commissions.
- Motley Fool•8 days ago
Why Iovance Biotherapeutics, Inc. Is Sinking Today
Recent gains, which didn't make much sense to begin with, were very short-lived.
- Motley Fool•11 days ago
Why Canopy Growth, SSR Mining, and Iovance Biotherapeutics Jumped Today
Find out which of these stocks had the best gains.
- GlobeNewswire•12 days ago
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock
Iovance Biotherapeutics, Inc. (IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offering of 22,000,000 shares of its common stock at a public offering price of $9.97 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be $219.3 million. In addition, Iovance has granted the underwriters a 30-day option to purchase up to 3,300,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions.
- Benzinga•12 days ago
The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
Here's a roundup of top developments in the biotech space over the last 24 hours. Amid the market mayhem, no biotech or medical device companies made it to 52-week highs. Down In The Dumps (Biotech stocks ...
- GlobeNewswire•12 days ago
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
Iovance Biotherapeutics, Inc. (IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Iovance intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less the underwriting discounts and commissions.
- GlobeNewswire•12 days ago
Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company’s Clinical Program
—FDA acknowledged acceptability of a single-arm cohort for registration in metastatic melanoma post PD-1 blocking antibody and, if BRAF mutation positive, a BRAF inhibitor or.
- GlobeNewswire•28 days ago
Iovance Biotherapeutics to Present at the 2018 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 26, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
- ACCESSWIRE•last month
Immuno Oncology & Targeted Therapy Companies Set to Breakout
HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance with Roche's Genentech to discover new cancer immunotherapies with an amazing $5 billion dollar deal. Roche is not the only major player in Immuno Oncology, and you can bet their competition is working to make their own splash announcements in the coming months.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and Iovance Biotherapeutics
NEW YORK, NY / ACCESSWIRE / September 7, 2018 / Arrowhead Pharmaceuticals exploded on positive data results on Thursday while shares of Iovance Biotherapeutics were deep in the red on its own concerning ...
- Investor's Business Daily•2 months ago
Biotech Dives After Experimental Lung Cancer Regimen Disappoints
Iovance Biotherapeutics stock toppled by double digits Thursday after a third of patients who received its experimental lung cancer regimen worsened following treatment.
- Motley Fool•2 months ago
Why Iovance Biotherapeutics Stock Is Crashing Today
A key clinical update sent Iovance's shares spiraling downward today.
- Zacks•2 months ago
Are Options Traders Betting on a Big Move in Lion Biotechnologies (IOVA) Stock?
Investors need to pay close attention to Lion Biotechnologies (IOVA) stock based on the movements in the options market lately.
- GlobeNewswire•2 months ago
Iovance Biotherapeutics Announces Clinical Trial Updates with Collaborators MD Anderson and Moffitt Cancer Center
Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced updates from its clinical collaborations with The University of Texas MD Anderson Cancer Center (MD Anderson) and Moffitt Cancer Center (Moffitt). Under the MD Anderson collaboration, the company announced that the first patient was dosed with LN-145 in the Phase 2, multi-arm clinical trial (NCT03449108). The company also announced that preliminary data from an investigator-sponsored Non-Small Cell Lung Cancer (NSCLC) study with Moffitt will be presented at the upcoming IASLC 19th World Conference on Lung Cancer (WCLC) on September 24, 2018 in Toronto, Canada.
- Associated Press•3 months ago
Iovance Biotherapeutics: 2Q Earnings Snapshot
The San Carlos, California-based company said it had a loss of 34 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- GlobeNewswire•3 months ago
Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
SAN CARLOS, Calif., Aug. 06, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today reported its ...
- ACCESSWIRE•3 months ago
Iovance Biotherapeutics Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Iovance Biotherapeutics Inc (NASDAQ: IOVA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern ...
- GlobeNewswire•3 months ago
Iovance Biotherapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
SAN CARLOS, Calif., July 30, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...
- ACCESSWIRE•3 months ago
Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks
LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).
- ACCESSWIRE•4 months ago
A Savvy Biotech Investor Is Betting Up To $25 Million Dollars On This $8 Stock Returning 250%... Or More?
Top-notch Great Point Partners is investing up to $25 million in Orgenesis' (ORGS) manufacturing subsidiary to enable global expansion. Company is already generating growing revenue, and this specialist healthcare fund investment substantiates the ORGS growth opportunity. Demand for CDMOs, like ORGS, is growing as more cell therapies (like gene therapies and CAR-T cells) come to market in the coming years.
- ACCESSWIRE•4 months ago
Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar
Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...
- Zacks•4 months ago
Iovance Biotherapeutics (IOVA) Jumps: Stock Rises 5.1%
Iovance Biotherapeutics (IOVA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Simply Wall St.•5 months ago
Iovance Biotherapeutics Inc (NASDAQ:IOVA): When Will It Breakeven?
Iovance Biotherapeutics Inc’s (NASDAQ:IOVA): Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicateRead More...
